Cipla

Cipla Limited is an Indian multinational pharmaceutical company headquartered in Mumbai. Cipla primarily focuses on developing medication to treat respiratory disease, cardiovascular disease, arthritis, diabetes, depression, paediatric and various other medical conditions. Cipla has 47 manufacturing locations across the world and sells its products in 86 countries. It is the third-largest drug producer in India.

Cipla Limited is an Indian multinational pharmaceutical company headquartered in Mumbai. Cipla primarily focuses on developing medication to treat respiratory disease, cardiovascular disease, arthritis, diabetes, depression, paediatric and various other medical conditions. Cipla has 47 manufacturing locations across the world and sells its products in 86 countries. It is the third-largest drug producer in India. ==Products and services== Cipla sells active pharmaceutical ingredients to other manufacturers as well as pharmaceutical and personal care products, including the anti-depressant escitalopram oxalate, lamivudine, and fluticasone propionate. Cipla is the world's largest manufacturer of antiretroviral drugs. In July 2020, the company announced the introduction of Gilead Sciences' Remdesivir under the brand name CIPREMI in India after reaching a voluntary licensing agreement with the parent company and DCGI approval for "restricted emergency use" in COVID-19 treatment of patients in critical condition. ==Operations== Cipla has 34 manufacturing units in 8 locations across India and a presence in over 80 countries. Exports accounted for 48% of its revenue for the 2013–14 fiscal year. Cipla spent 517 crore (5.4% of their revenue) in the 2013–14 fiscal year on R&D activities. The primary focus areas for R&D were development of new formulations, drug-delivery systems, and APIs. Cipla also cooperates with other enterprises in areas such as consulting, commissioning, engineering, project appraisal, quality control, know-how transfer, support, and plant supply. == Listings and shareholding== The equity shares of Cipla are listed on the Bombay Stock Exchange, where it is a constituent of the BSE SENSEX index, and the National Stock Exchange of India, where it is a constituent of the CNX Nifty. Its Global Depository Receipts (GDRs) are listed on the Luxembourg Stock Exchange. As of 31 December 2022, the promoter group, Y. K. Hamied and his family, held around 33.61% equity shares in Cipla. Individual shareholders hold approximately 14.72% of its shares. SBI Mutual Fund, LIC etc. are the largest non-promoter shareholders in the Company. In January 2024, Samina Hamied resigned from her position as the Executive Vice Chairperson of Cipla. She continued to serve the company as a non-executive director subject to rotational retirement. ==Awards and recognitions== In 1980, Cipla won Chemexcil Award for Excellence for exports. In 2006, Cipla won Dun & Bradstreet American Express Corporate Awards. In 2007, Forbes included Cipla in the 200 'Best under a billion' list of best small Asian companies. In 2012, Cipla received the Thomson Reuters India Innovation Award. In 2015, Cipla stood third in the India's Most Reputed Brands (Pharmaceutical) list, in a study conducted by BlueBytes, a Media Analytics firm in association with TRA Research, a brand insights organization (both part of the Comniscient Group). ==Criticism== ===Emergency contraception=== In August 2007, Cipla launched an emergency contraception drug "i-pill" sold over the counter. The drug sparked controversy as it was available without prescription and contained a large amount of API per dosage. ===Generic drugs=== In the late 1960s, Cipla began manufacturing a new, patented drug, propranolol, without the permission of the drug's patent holder, Imperial Chemical Industries; a protest was filed with the Indian government. The CEO of Cipla pressured the government of Indira Gandhi to change India's patent laws to eliminate patents that directly covered drugs, and instead to allow only patents that covered methods to make drugs so that Cipla could produce low-priced generic drugs. Since then, Cipla has also produced a low-cost drug to treat HIV, and expanded operations into several developing countries. The changes made led to criticism of both India's patent laws and Cipla. India reinstated patents on drugs in 2005. ==See also== Pharmaceutical industry in India Generic drug List of pharmaceutical companies ==References== ==External links==

Text derived from https://en.wikipedia.org/w/index.php?oldid=1368848911 under CC BY-SA 4.0; modifications have been made.